Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Berzosertib |
Synonyms | |
Therapy Description |
Berzosertib (VX-970) is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479, PMID: 32109490). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Berzosertib | VX-970|VE-822|M6620 | ATR Inhibitor 16 | Berzosertib (VX-970) is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479, PMID: 32109490). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM del | prostate cancer | sensitive | Berzosertib | Preclinical - Cell culture | Actionable | In a preclinical study, ATM-deficient prostate cancer cell lines were sensitive to treatment with Berzosertib (VX-970) in culture, demonstrating inhibition of cell growth (PMID: 32127357). | 32127357 |
ATM loss | colorectal cancer | sensitive | Berzosertib | Phase I | Actionable | In a Phase I trial, Berzosertib (VX-970) treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)). | detail... |
CHEK1 over exp | lung small cell carcinoma | sensitive | Berzosertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, small cell lung cancer cell lines, which expressed high levels of CHEK1, demonstrated sensitivity to Berzosertib (VX-970) treatment, resulting in decreased viability in culture and reduced tumor growth in xenograft models (PMID: 29138515). | 29138515 |
IDH1 R132H | Advanced Solid Tumor | sensitive | Berzosertib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing IDH1 R132H demonstrated increased sensitivity to Berzosertib (VX-970)-induced growth inhibition in culture (PMID: 28148839). | 28148839 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02595892 | Phase II | Berzosertib Gemcitabine | Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03718091 | Phase II | Berzosertib | M6620 (VX-970) in Selected Solid Tumors | Completed | USA | 0 |
NCT04052555 | Phase I | Berzosertib | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02627443 | Phase II | Carboplatin + Gemcitabine Berzosertib | Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02589522 | Phase I | Berzosertib | VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |